TrialThe Lancet. Microbe2025

Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.

Chama Chanda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.